U.S. Stock Market Midday Update
BiomX rose 12.91%. Based on recent key news:
<ol>
<li>
On December 8, BiomX announced the termination of the BX004 trial, planning to cut costs and lay off employees. This decision was made after a safety review by an independent data monitoring committee, although BX011 still shows potential in Staphylococcus aureus infections. This news has raised market attention on the company's future strategy, leading to a 12.91% increase in stock price. Source: Reuters
</li>
<li>
On December 8, BiomX released an announcement through the EDGAR system, emphasizing the company's responsibility for information. This move increased investor confidence in the company's transparency, further driving up the stock price. Source: EDGAR
</li>
<li>
No other significant news recently. The biotechnology industry has been volatile lately and requires attention.
</li>
</ol>
Top Stocks by Industry Trading Volume
AbbVie rose 0.39%. Based on recent news,
<ol>
<li>
On December 10, analyst Rajesh Kumar upgraded AbbVie's rating, believing it is expected to stabilize growth after fluctuations in 2025. The rating upgrade had a positive impact on the stock price, driving AbbVie's stock up. Source: MarketBeat
</li>
<li>
On December 9, AbbVie's collaboration with Ose became a focal point, as the advancement of clinical trials may unlock more funding milestones, enhancing market confidence. Source: MarketBeat
</li>
<li>
On December 8, market attention increased on collaborations between large pharmaceutical companies and biotechnology firms, and AbbVie's strategic choices may influence future stock price trends. Source: MarketBeat The trend of collaboration in the biotechnology industry is significant, with active capital inflows.
</li>
</ol>
Abivax SA rose 3.34%. Based on recent news,
<ol>
<li>
On December 10, market speculation suggested that Eli Lilly might acquire Abivax, driving up the stock price. Abivax's core product under research, obefazimod, is used to treat inflammatory diseases such as ulcerative colitis. This news caused the company's stock price to rise over 10% on the Paris stock market, with a market capitalization climbing to approximately €8 billion. Source: Zhitong Finance
</li>
<li>
On December 10, Stifel analyst Damien Choplain stated that the rise in Abivax's stock price was mainly driven by speculation of a potential acquisition deal. Eli Lilly did not comment on this. Source: Zhitong Finance
</li>
<li>
On December 10, Abivax's stock price surged significantly after announcing positive results from the Phase III clinical trial of its core drug Obefazimod in July. Source: Zhitong Finance Speculation about potential acquisition deals has driven up the stock price.
</li>
</ol>
Regeneron Pharmaceuticals rose 2.92%. Based on recent key news:
<ol>
<li>
On December 7, Regeneron's LYNOZYFIC™ showed significant efficacy in newly diagnosed multiple myeloma, supporting its potential as a first-line treatment foundation. This news has boosted market confidence in the drug, driving up the stock price
</li>
<li>
On December 8, the company's Vice President Murphy Andrew J and Pitofsky Jason submitted share repurchase documents, demonstrating insider confidence in the company's future development, further boosting the stock price.
</li>
<li>
On December 8, REGEN-COV® received FDA authorization during the COVID-19 pandemic. Although the authorization has ended, its successful application during the pandemic continues to have a positive impact on the company. The biotechnology industry has recently performed strongly, with significant capital inflows.
</li>
</ol>
Stocks ranked at the top of the industry by market capitalization
Amgen rose 0.69%. Based on recent key news:
<ol>
<li>
On December 10, Amgen announced a quarterly dividend increase of 5.9% to $2.52 per share. This move has enhanced investor confidence and driven the stock price up. According to the latest stock price, the annual yield is 3.2%. Source: WSJ
</li>
<li>
On December 10, Amgen announced a $900 million investment in Ohio to promote local economic development and create jobs. This investment plan reflects the company's expansion strategy and boosts market sentiment. Source: MarketBeat
</li>
<li>
On December 10, analyst ratings show Amgen as &#34;Moderate Buy,&#34; but it is not included in the top recommended stocks list. This rating may affect investors' expectations for the company's future growth. Source: MarketBeat The pharmaceutical industry has recently shown stable performance, with significant capital inflows
</li>
</ol>

PHGE

BiomX rose 12.91%; AbbVie rose 0.39%, with a trading volume of USD 550 million; Abivax SA rose 3.34%, with a trading volume of USD 381 million; Regeneron Pharmaceuticals rose 2.92%, with a trading volume of USD 314 million; Amgen rose 0.69%, with a market capitalization of USD 170.2 billion

U.S. Stock Market Midday Update: Termination of Trial Layoff Plan Draws Attention, BiomX Stock Price Rises 12.91% Against the Trend